Press push Avacta upwards

AIM-listed biotechnology firm Avacta Group (LON:AVCT) has seen its share price climb by 7.27% to 196.30p (as of 15:25 GMT) after press speculation regarding UK Government take-up of its COVID lateral flow tests. The company has outlined certain inaccuracies in these reports including that the trial results quoted referred to anterior nasal testing rather than saliva.

Management said that the product was undergoing further testing with a larger sample size and they hope to bring it to market towards the end of the first quarter.